Rare but serious gastrointestinal complications have been reported in post-marketing surveillance, including: Acute pancreatitis : If suspected, the GLP-1 agonist should be stopped immediately and not restarted if pancreatitis is confirmed Severe gastroparesis : Rare post-marketing reports of severe delayed gastric emptying Intestinal obstruction : Very rare cases reported in post-marketing surveillance Patients should be advised to seek urgent medical help via NHS 111, A&E or 999 as appropriate if they experience severe or persistent abdominal pain, persistent vomiting, abdominal distension, inability to pass stool or gas, or bloody diarrhoea whilst taking GLP-1 agonists
With all fiber supplements, increase your intake of water to keep things moving smoothly
Therefore, MIC/B-12 injections may contribute to improved overall appearance and health in these areas
FradinhoPNiccolaiASoaresRRodolfiLBiondiNTrediciMRet al
Along with this, 100 M IBU was detected to have a protective effect on plant growth and antioxidant status upon subsequent 48 h exposure to 100 mM NaCl
M.SontheimerH